Skip to main content

Table 1 Prevalence of immune cell types in sentinel vs. non-sentinel nodes and in positive vs. negative SLNs

From: Immune cell profile of sentinel lymph nodes in patients with malignant melanoma – FOXP3+ cell density in cases with positive sentinel node status is associated with unfavorable clinical outcome

Study (reference)

Tumor

Number of

Number of

Dendritic cells

Mature DCs

Plasmacytoid DCs

T cells

Regulatory T cells

 

type

patients (SLNs)

+ / - SLNs

SLN vs. NSLN

+ vs. - SLN

SLN vs. NSLN

+ vs. - SLN

SLN vs. NSLN

+ vs. - SLN

SLN vs. NSLN

+ vs. - SLN

SLN vs. NSLN

+ vs. - SLN

Compared to NSLNs of the same patient cohort

             

Cochran et al. 2001 [3]

melanoma

11 (21)

10 / 11

lower

NT

NT

NT

NT

NT

NT

NT

NT

NT

Botella-Estrada et al. 2005 [4]

melanoma

10 (17)

1 / 16

higher

NT

no diff.

NT

NT

NT

NT

NT

NT

NT

Gerlini et al. 2007 [20]

melanoma

27 (39)

8 / 31

NT

NT

NT

NT

NT

higher

NT

NT

NT

NT

Speeckaert et al. 2011 [14]

melanoma

116 (116)

26 / 90

NT

NT

NT

NT

NT

NT

NT

NT

NT

higher

Ma et al. 2012 [15]

melanoma

84 (84)

31 / 53

NT

lower

NT

higher

NT

NT

NT

NT

NT

higher

Huang et al. 2000 [2]2

breast cc.

21 (21)

not spec.

lower

NT

lower

NT

NT

NT

lower

NT

NT

NT

Kohrt et al. 2005 [7]2

breast cc.

29 (29)

29 / 0

lower

NT

NT

NT

NT

NT

lower (CD4+)

NT

NT

NT

Bembenek et al. 2008 [6]

breast cc.

79 (114)

51 / 283

NT

NT

higher

NT

NT

NT

NT

NT

NT

NT

Ishigami et al. 2003 [11]

gastric cc.

27 (27)

8 / 19

no diff.

no diff.

NT

NT

NT

NT

no diff.

no diff.

NT

NT

Lee et al. 2011 [13]

gastric cc.

64 (64)

45 / 193

NT

NT

NT

no diff.

NT

NT

NT

no diff.

NT

higher

Sakakura et al. 2005 [5]

oral cc.

12 (41)

0 / 41

higher

NT

no diff.

NT

NT

NT

NT

NT

NT

NT

Compared to non-tumor control nodes

             

Mansfield et al. 2011 [10]

melanoma

20 (20)

8 / 12

NT

NT

lower

no diff.

no diff.

no diff.

lower (CD8+)

no diff.

no diff.

no diff.

Poindexter et al. 2004 [12]

breast cc.

50 (50)

25 / 25

no diff.

no diff.

no diff.

lower

NT

NT

NT

NT

NT

NT

Mansfield et al. 2009, 2011 [8, 9]

breast cc.

47 (47)

36 / 11

no diff.

no diff.

higher

lower

no diff.

no diff.

higher (CD8+)

no diff.

no diff.

higher

  1. Columns SLN vs. NSLN: comparison of negative SLNs to negative NSLNs or controls (except in studies [2] and [7]); columns + vs. - SLN: comparison of positive to negative SLNs.
  2. 1SLNs and NSLNs of unspecified status were compared; 2positive SLNs were compared to mixed (+ and -) NSLNs; also compared to non-tumor controls, with similar results
  3. 3number of patients with + / - SLN status; NT: not tested;no diff.: no difference; not spec.: not specified.